Engineered t cells take on ovarian cancer in new trial
NCT ID NCT03184753
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tests a new treatment for advanced ovarian cancer using a patient's own immune cells, called T cells, that are modified in a lab to better recognize and attack the cancer. About 100 women with stage III or IV ovarian cancer will receive these modified cells. The main goals are to check safety and see if the cells can trigger an anti-cancer response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OC-IgT cells (a patient's own immune cells modified to target ovarian cancer)
What this could lead to
If successful, this could point toward a new treatment option for advanced ovarian cancer that uses the patient's own immune system.
What could go wrong
This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. The treatment may cause side effects or not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••